MYCN and neuroblastoma: Inhibition of PRMT5 led to a dramatic curtailment of MYCN-activated genes, including gene signatures strongly associated with poor prognosis in neuroblastoma [22,51], BRD4 inhibition of neuroblastoma with JQ-1 [52] and cell-cycle resolved MYCN-activated genes from RNA sequencing in cell-cycle-synchronized neuroblastoma cells [53].